Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,476
datasets available to search
ShareScore release 0.9.0
Dataset results
3,476 results for “Parkinson disease”
Figure 1 from: Kotvitska A, Prokopenko O (2020) Determination of social and economic accessibility of drugs for treatment of Parkinson's disease on the basis of modern approaches. Pharmacia 67(4): 215-221. https://doi.org/10.3897/pharmacia.67.e46586
Figure 1 Algorithm for conducting studies to determine the social and economic affordability of medicines for the treatment of PD.
Probiotic-prebiotic therapy improved constipation and gut motility in Parkinson's disease: Randomised controlled trial
<p><b>Objective</b>: We determined the effectiveness of a multi-strain probiotic-prebiotic combination on constipation symptoms and gut motility in PD patients with constipation.</p> <p><b>Methods: </b>PD<b> </b>patients with constipation (ROME III criteria) were randomized to receive a multi-strain probiotic (<i>Lactobacillus sp</i> and <i>Bifidobacterium sp at </i>30 X 10<sup>9</sup> CFU) with fructo-oligosaccaride (prebiotic) or placebo (fermented milk) twice daily for 8 weeks. Primary outcomes were changes in the presence of constipation symptoms using 9 items of Garrigues Questionnaire (GQ), which included an item on bowel opening frequency. Secondary outcomes were whole gut transit time (WGTT), quality of life (PDQ39-SI), motor (MDS-UPDRS) and non-motor symptoms (NMSS).</p> <p><strong>Results:</strong> Of 55 recruited<b>, </b>48 patients completed the study: 22 received probiotic and 26 received placebo. At 8 weeks, the item on bowel opening frequency (BOF) of GQ showed a higher mean weekly BOF in the probiotic group compared to placebo [4.18 (SD 1.44) vs 2.81(SD 1.06), (mean difference 1.37, 95% CI 0.68, 2.07, uncorrected <i>p</i><0.001). Patients in the probiotic group reported five times higher odds (odds ratio=5.48, 95% CI 1.57, 19.12, uncorrected <i>p</i>=0.008) for increasing BOF (< 3 to 3-5 to >5 times/week) compared to the placebo group. Between-group differences were observed in the WGTT [77.32 (SD 55.35) hours vs 113.54 (SD 61.54) hours], (mean difference -36.22, 95% CI -68.90, -3.54, uncorrected <i>p</i>=0.030) and the mean change in WGTT [58.05 (SD 59.30) vs 20.73 (60.48) hours], (mean difference 37.32, 95% CI 4.00, 70.63, uncorrected <i>p</i>=0.028). No between-groups differences were observed in the NMSS, PDQ39-SI, MDS-UPDRS II, III, scores. Four patients in the probiotics group experienced mild reversible side effects.</p> <p><b>Conclusion:</b> This study provides Class I evidence that consumption of multi-strain probiotics with prebiotic over 8 weeks improved bowel opening frequency and whole gut transit time.</p>
Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia
<p><span><span><span><span><span><span><span><span><span><span><span>MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, <span><span>has been</span></span> applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. MRgFUS could become a therapeutic tool for drug delivery of putative neurorestorative therapies. Treatment for Parkinson's disease with dementia (PDD) is an important unmet need. We <span><span>initiated a prospective, single-arm, non-randomized, proof-of-concept, safety and feasibility</span></span> phase I clinical trial <span><span>(NCT03608553), which is still in progress. The primary outcomes of the study were to demonstrate the safety, feasibility and reversibility of BBB disruption in PDD,</span></span> targeting the right parieto-occipito-temporal cortex where cortical pathology is foremost in this clinical state. <span><span>Changes in </span></span><span><span>β</span></span><span><span>-</span></span><span><span>amyloid burden, brain metabolism after treatments and neuropsychological assessments, were analyzed as exploratory measurements.</span></span> <span><span>Five patients were recruited from October 2018 until May 2019, and</span></span> received two <span><span>treatment</span></span> sessions separated by 2-3 weeks. <span><span>The results are set out in a descriptive manner.</span></span> Overall, this procedure was feasible and reversible with no serious clinical or radiological side effects. <span><span>We report BBB opening in the parieto-occipito-temporal junction in 8/10 treatments in 5 patients as demonstrated by gadolinium enhancement. In all cases the procedures were uneventful and no side effects were encountered associated with BBB opening.</span></span> From pre- to post-treatment, mild cognitive improvement was observed, and no major changes were detected in amyloid or fluorodeoxyglucose PET. MRgFUS-BBB opening in PDD is thus safe, reversible, and can be <span><span>performed</span></span> repeatedly. This study provides encouragement for the concept of BBB opening for drug delivery to treat dementia in PD and other neurodegenerative disorders.</span></span></span></span></span></span></span></span></span></span></span></p>
Data from: Longitudinal analysis of impulse control disorders in Parkinson's disease
Objective: To investigate the longitudinal dose-effect relationship between dopamine replacement therapy and impulse control disorders (ICDs) in Parkinson's disease (PD). Methods: We used data from a multicentre longitudinal cohort of consecutive PD patients with ≤5y disease duration at baseline followed annually up to 5y. ICDs were evaluated during face-to-face semi-structured interviews with movement disorder specialists. Generalized estimating equations Poisson models with robust variance were used to study the association between several time-dependent definitions of dopamine agonist (DA) use, taking dose and duration of treatment into account, and ICDs at each visit; other antiparkinsonian drugs were also examined. Results: Among 411 patients (40.6% women; mean age=62.3y, average follow-up=3.3y, SD=1.7y), 356 (86.6%) took DA at least once since disease onset. In 306 patients without ICDs at baseline, the 5y cumulative incidence of ICDs was 46.1% (95% CI=37.4-55.7; DA ever-users=51.5% [41.8-62.1]; DA never-users=12.4% [4.8-30.0]). ICDs prevalence increased from 19.7% at baseline to 32.8% after 5y. ICDs were associated with ever DA use (prevalence ratio, PR=4.23 [1.78, 10.09]). Lifetime average daily dose and duration of treatment were independently associated with ICDs, with significant dose-effect relations. Similar analyses for levodopa were not in favour of a strong association. ICDs progressively resolved after DA discontinuation. Conclusions: In this longitudinal study of PD patients characterized by a high prevalence of DA treatment, the 5y cumulative incidence of ICDs was ~46%. ICDs were strongly associated with DA use, with a dose-effect relationship; both increasing duration and dose were associated with ICDs. ICDs progressively resolved after DA discontinuation.
Data from: Effect of polygenic load on striatal dopaminergic deterioration in Parkinson's disease
Objective: To investigate the effect of polygenic load on the progression of striatal dopaminergic dysfunction in patients with Parkinson's disease (PD). Methods: Using data from 335 PD patients in the Parkinson's Progression Markers Initiative (PPMI) database, we investigated the longitudinal association of PD-associated polygenic load with changes in striatal dopaminergic activity as measured by 123I-N-3-fluoropropyl-2-beta-carboxymethoxy-3beta-(4-iodophenyl) nortropane (123I-FP-CIT) single photon emission computed tomography (SPECT) over 4 years. PD-associated polygenic load was estimated by calculating weighted genetic risk scores (GRS) using: i) all available 27 PD-risk single nucleotide polymorphisms (SNPs) in the PPMI database (GRS1); and ii) 23 SNPs with minor allele frequency > 0.05 (GRS2). Results: GRS1 and GRS2 were correlated with younger age-at-onset in PD patients (GRS1, Spearman's rho = -0.128, p = 0.019; GRS2, Spearman's rho = -0.109, p = 0.047). Although GRS1 did not show an association with changes in striatal 123I-FP-CIT availability, GRS2 was associated with a slower decline of striatal dopaminergic activity (interactions with disease duration in linear mixed model; caudate nucleus, estimate = 0.399, SE = 0.165, p = 0.028; putamen, estimate = 0.396, SE = 0.137, p = 0.016). Conclusions: Our results suggest that genetic factors for PD risk may have heterogeneous effects on the striatal dopaminergic degeneration, and some factors may be associated with a slower decline of dopaminergic activity. Composition of PD-progression specific GRS may be useful in predicting disease progression in patients.
Data from: Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder producing a variety of motor and cognitive deficits with the causes remaining largely unknown. The gradual loss of the nigrostriatal pathway is currently considered the pivotal pathological event. To better understand the progression of PD and improve treatment management, defining the disease on a structural basis and expanding brain analysis to extra-nigral structures is indispensable. The anatomical complexity and the presence of neuromelanin, make the use of non-human primates an essential element in developing putative imaging biomarkers of PD. To this end, ex vivo T2-weighted magnetic resonance images were acquired from control and 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated marmosets. Volume measurements of the caudate, putamen, and substantia nigra indicated significant atrophy and cortical thinning. Tensor-based morphometry provided a more extensive and hypothesis free assessment of widespread changes caused by the toxin insult to the brain, especially highlighting regional cortical atrophy. The results highlight the importance of developing imaging biomarkers of PD in non-human primate models considering their distinct neuroanatomy. It is essential to further develop these biomarkers in vivo to provide non-invasive tools to detect pre-symptomatic PD and to monitor potential disease altering therapeutics.
Objective measurement in routine care of people with Parkinson's disease improves outcomes
<p>It is common in medicine to titrate therapy according to target ranges of objectively measured parameters. Objective measurement of motor function is available for Parkinson's Disease (PD), making it possible to optimise therapy and clinical outcomes. In this study, an accelerometry-based measurement and predefined target ranges were used to assess motor function in a Northern Tasmania PD cohort managed by a Movement Disorder clinic. Approximately 40% (n=103) of the total PD population participated in this study and motor scores were within target in 22%. In the 78% above target, changes in oral therapy were recommended in 74%, Advanced Therapy in 12% and treatment was contraindicated in 9%. Following changes in oral therapy, there was a further objective measurement and clinical consultation to establish whether scores had reached target range: if so subjects left the study, otherwise further changes of therapy were recommended (unless contraindications were present). Seventy-seven cases completed the study, with 48% achieving target (including 22% at outset), Advanced Therapy recommended in 19% and contraindications preventing any change in therapy in 17%. In the 43% of cases in whom oral therapy was changed, total UPDRS improved significantly (effect size =8) as did the PDQ39 in cases reaching target. NMS Quest and MOCA scores also improved significantly. This study shows that many people in a representative cohort of PD would benefit from objective assessment and treatment of their PD features against a target. </p>
Age-induced midbrain-striatum assembloid models early phenotypes of Parkinson's disease
Open the record for dataset details and reuse information.
Nigrostriatal Tau Pathology in parkinsonism and Parkinson's disease
Open the record for dataset details and reuse information.
UNRAVELLING CELL TYPE SPECIFIC RESPONSE TO PARKINSON'S DISEASE AT SINGLE CELL RESOLUTION
Open the record for dataset details and reuse information.
Presence of skin α-synuclein deposits discriminates Parkinson's disease from progressive supranuclear palsy and corticobasal syndrome
<p>Dataset </p>
Association of gyrification pattern, white matter changes and phenotypic profile in patients with Parkinson's disease
<p><b>Objective:</b> To investigate the cortical gyrification changes as well as their relationships with white matter (WM) microstructural abnormalities in the akinetic-rigid (AR) and tremor-dominant (TD) subtypes of Parkinson's disease (PD).</p> <p><b>Methods:</b> Sixty-four patients with the AR subtype, 26 patients with the TD subtype and 56 healthy controls (HCs) were included in this study. High-resolution T1-weighted and diffusion-weighted images were acquired for each participant. We computed local gyrification index (LGI) and fractional anisotropy (FA) to identify the cortical gyrification and WM microstructural changes in the AR and TD subtypes.</p> <p><b>Results: </b>Compared with HCs, patients with the AR subtype showed decreased LGI in the precentral, postcentral, inferior and superior parietal, middle and superior frontal/temporal, anterior and posterior cingulate, orbitofrontal, supramarginal, precuneus, and some visual cortices, and decreased FA in the corticospinal tract, inferior and superior longitudinal fasciculus, inferior fronto-occipital fasciculus, forceps minor/major, and anterior thalamic radiation. Decreases in LGI and FA of the AR subtype were found to be tightly coupled. LGIs of the left inferior and middle frontal gyrus correlated with the mini-mental state examination and the Hoehn and Yahr scores of patients with the AR subtype. Patients with the TD subtype showed no significant change in the LGI and FA compared with patients with the AR subtype and HCs.</p> <p><b>Conclusions:</b> Our results suggest that cortical gyrification changes in PD are motor phenotype-specific and are possibly mediated by the microstructural abnormalities of the underlying WM tracts.</p>
Data from: Functional role of the cerebellum in Parkinson's disease: a PET study
<p><span><b>Objectives:</b> To test for cerebellar involvement in motor and nonmotor impairments in Parkinson's disease (PD), and to determine patterns of metabolic correlations with supratentorial brain structures, we correlated clinical motor, cognitive and psychiatric scales with cerebellar metabolism.</span></p> <p><span><b>Methods: </b>We included 90 patients with PD. Motor, cognitive and psychiatric domains were assessed, and resting-state <sup>18</sup>FDG-PET metabolic imaging was performed. The motor, cognitive and psychiatric scores were entered separately in a principal component analysis. We looked for correlations between these three principal components and cerebellar metabolism. Furthermore, we extracted the mean glucose metabolism value for each significant cerebellar cluster and looked for patterns of cerebrum‑cerebellum metabolic correlations.</span></p> <p><span><b>Results:</b> Severity of impairment was correlated with increased metabolism in the anterior lobes and vermis (motor domain), and the right Crus I, Crus II, and declive (cognitive domain), and the right Crus I and Crus II (psychiatric domain). There were no results surviving multiple testing corrections regarding the psychiatric domain. Moreover, we found distributed and overlapping ‑ but not identical‑ patterns of metabolic correlations for motor and cognitive domains. Specific supratentorial structures (cortical structures, basal ganglia, and thalamus) were strongly correlated with each of the cerebellar clusters. </span></p> <p><span><b>Conclusions:</b> These results confirm the role of the cerebellum in nonmotor domains of Parkinson's disease, with differential but overlapping patterns of metabolic correlations suggesting the involvement of cerebello‑thalamo-striatal‑cortical loops.</span></p>
Various PubChem lists for Parkinson's Disease and related disorders
<p>Collection of 8 lists of chemicals associated to Parkinson's disease (PD) and related disorders.</p> <p>PubChem functionality relating Medical Subject Headings (MeSH) information on certain disease endpoints to chemicals was explored to create the lists.</p> <p>The following table describes the mentioned lists. </p> <table> <tbody> <tr> <td>Name</td> <td>Description</td> </tr> <tr> <td>PD-MetFrag</td> <td>MetFrag database of 21,303 chemicals related to PD, PD Secondary, Parkinsonian disorders, Lewy body disease, Alzheimer disease, dementia, Huntington disease and neurodegenerative disorders</td> </tr> <tr> <td>PD-CTD</td> <td>List of 296 chemicals associated to PD in the Comparative Toxicogenomic Database (CTD), extracted via the CTD integration within PubChem</td> </tr> <tr> <td>D003248 </td> <td>List of 3,943 chemicals related to Constipation Disorders</td> </tr> <tr> <td>D000857 </td> <td>List of 688 chemicals related to Olfactory Impairment</td> </tr> <tr> <td>D003863 </td> <td>List of 363 chemicals associated to Depression Disorders</td> </tr> <tr> <td>D001008 </td> <td>List of 8,433 chemicals associated to Anxiety Disorders</td> </tr> <tr> <td>D020920</td> <td>List of 59 chemicals related to Dyssomnias</td> </tr> <tr> <td>D012893</td> <td>List of 2,781 chemicals associated to Sleep Wake Disorders</td> </tr> </tbody> </table> <p>Further details can be found in the published manuscript (https://doi.org/10.1007/s00216-022-04207-z).</p>
Parkinson's disease-related brain metabolic patterns and neurodegeneration in isolated REM sleep behavior disorder
<p><span><b>Objective</b>: To elucidate the role of Parkinson's disease (PD)-related brain metabolic patterns as a biomarker in isolated rapid-eye-movement sleep behavior disorder (iRBD) for future disease conversion.</span></p> <p><span><b>Method</b>: This is a prospective cohort study consisting of 30 iRBD patients, 25 de novo PD patients with a premorbid history of RBD, 21 long-standing PD patients on stable treatment and 24 healthy controls. iRBD group was longitudinally followed up. All participants underwent <sup>18</sup>F-Fluorodeoxyglucose (FDG) PET and were evaluated with olfaction, cognition, and the Movement disorders society-Unified PD Rating Scale (MDS-UPDRS) at baseline. From FDG-PET scans, we derived metabolic patterns from the long-standing PD group (PD-RP) and de novo PD group with RBD (dnPDRBD-RP). Subsequently, we calculated the PD-RP and dnPDRBD-RP scores in iRBD patients. We validated the metabolic patterns in each PD group and separate iRBD cohort (<i>n</i>=14).</span></p> <p><span><b>Result</b>: The two patterns significantly correlated with each other and were spatially overlapping yet distinct. The MDS-UPDRS motor scores significantly correlated with PD-RP (<i>p</i> = 0.013) but not with dnPDRBD-RP (<i>p</i> = 0.076). In contrast, dnPDRBD-RP correlated with olfaction in butanol threshold test (<i>p</i> = 0.018) in iRBD subjects, but PD-RP did not (<i>p</i> = 0.21). High dnPDRBD-RP in iRBD patients predicted future phenoconversion with all cut-off ranges from 1.5 to 3 standard deviations of the control value, whereas predictability of PD-RP was only significant in a partial range of cut-off.</span></p> <p><b>Conclusion:</b> The dnPDRBD-RP is an efficient neuroimaging biomarker that reflects prodromal features of PD and predicts phenoconversion in iRBD that can be applied individually.</p>
Tabular datasets for for Morrone Parfitt, G., Coccia, E., Goldman, C. et al. Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson's disease model. Nat Commun 15, 447 (2024). https://doi.org/10.1038/s41467-024-44732-2
Open the record for dataset details and reuse information.
Serum metabolome and gut microbiome analysis of Parkinson's disease
<p>Serum metabolomics and gut microbiome analysis of individual with Parkinson's disease (PD) and healthy control</p>
Supplementary Datasets for Decoding the genetic markers symphony in Parkinson's Disease
Open the record for dataset details and reuse information.
"THE APPLICATION OF MIRAPEX PD EXTENDED-RELEASE IN MONOTHERAPY MODE IN THE EARLY STAGES OF PARKINSON'S DISEASE IN THE REPUBLIC OF UZBEKISTAN."
Open the record for dataset details and reuse information.
Robot-induced hallucinations in Parkinson's disease depend on altered sensorimotor processing in fronto-temporal network
<p>Dataset of the fMRI study in healthy subjects from "Robot-induced hallucinations in Parkinson’s disease depend on altered sensorimotor processing in fronto-temporal network"</p> <p>It contains the fMRI data from the healthy subjects that performed the robotic stimulation task inducing the presence hallucination.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.